Q-omics provides the consensus-scored ADORA2A profile across patient tissues and cancer cell-line models. ADORA2A expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ADORA2A is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ADORA2A RNA expression shows 18,736 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where ADORA2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADORA2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADORA2A survival associations across molecular data types. ADORA2A RNA expression shows survival associations in the most cancer types (18), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADORA2A RNA expression–survival associations across cancer types. High ADORA2A expression shows unfavorable associations in ACC and LUSC, but favorable associations in HNSC, SKCM, KIRC and PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ADORA2A RNA expression.
This table summarizes ADORA2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ADORA2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADORA2A shows lower tumor expression in KICH, COAD and LUAD and higher tumor expression in KIRC, LIHC and BRCA. The KIRC box plot shows higher ADORA2A RNA expression in tumor versus normal tissue (log2 FC = +0.410, t-test p < 0.001).
This table shows molecular features associated with ADORA2A in patient tissues and cancer cell lines. In patient samples, ADORA2A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ADORA2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
